Loading
Latest filing published 20 Aug 2026 for Interpace Biosciences, INC..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Thomas W. Burnell is a declared insider of Interpace Biosciences, Inc. (chief executive), with filings sourced from SEC (Form 4). In total, 5 filings cover trades dated from 1 December 2020 to 20 August 2026.
No open-market sale appears; the market trades are 1 purchase worth €77k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 3 share grants and 1 option exercise.
On 20 August 2026 came the latest disclosure, an option exercise in Interpace Biosciences, Inc. The last purchase on record was published on 25 May 2021, which is 1,978 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations